NCT05153096View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

NBL-015

NBL-015 by intravenous infusion

Trial Locations (1)

200032

Zhongshan Hospital affiliated to Fudan University, Shanghai

Sponsors
All Listed Sponsors
lead

NovaRock Biotherapeutics, Ltd

INDUSTRY

NCT05153096 - Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter